抗次黃嘌呤磷酸核糖基轉(zhuǎn)移酶1(HPRT1)多克隆抗體
Anti-Hypoxanthine Phosphoribosyltransferase 1 (HPRT1) Polyclonal Antibody
HGPRT; HGPRTase; HPRT; Lesch-Nyhan Syndrome; Hypoxanthine-guanine phosphoribosyltransferase
- 編號(hào)FAA717Hu01
- 物種Homo sapiens (Human，人)相同的名稱(chēng)，不同的物種。
- 效價(jià)-
- Ig類(lèi)型IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無(wú)標(biāo)記物
- 激發(fā)波長(zhǎng)-
- 單次使用量1-5 μl
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 且適物種-
- 應(yīng)用Flow cytometry.
- 下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格25test50test100test200test500test
- 價(jià)格¥ 720¥ 1200¥ 1920¥ 2400¥ 4200
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
HepG2 human hepatocellular carcinoma cell line was stained with rabbit Anti-human HPRT1 Polyclonal Antibody (Catalog # FAA717Hu01, filled red histogram) or Isotype control antibody (Catalog # IS067-Rb01, filled green histogram), followed by APC-conjugated Anti-rabbit IgG Secondary Antibody (Catalog # SAA544Rb15). Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100.
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
用法
For flow cytometry, the suggested use of this reagent is 1-5 μl per 10^6 cells in 100 μl volume.
Optimal working dilutions could be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)一年。避免反復(fù)凍融。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA717Hu01 | 次黃嘌呤磷酸核糖基轉(zhuǎn)移酶1(HPRT1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA717Hu01 | 次黃嘌呤磷酸核糖基轉(zhuǎn)移酶1(HPRT1)多克隆抗體 | WB,IHC,FCM |
| FAA717Hu01 | 抗次黃嘌呤磷酸核糖基轉(zhuǎn)移酶1(HPRT1)多克隆抗體 | Flow cytometry. |
| MAA717Hu22 | 次黃嘌呤磷酸核糖基轉(zhuǎn)移酶1(HPRT1)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA717Hu | 次黃嘌呤磷酸核糖基轉(zhuǎn)移酶1(HPRT1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA717Hu | 次黃嘌呤磷酸核糖基轉(zhuǎn)移酶1(HPRT1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| J Crohns Colitis. | Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of Tenascin C.[Pubmed:25518051] |
| J Crohns | Response to infliximab therapy in ulcerative colitis is associated with decreased monocyte activation, reduced CCL2 expression and downregulation of tenascin C[PubMed: 25518051] |
| Molecular Biology Reports | Increased ENT2 Expression and Its Association With Altered Purine Metabolism in Different Stages of Colorectal Cancer Cell Lines[] |